dsm-firmenich enzymatic solution accelerates production of lactose-free targets
dsm-firmenich’s latest addition to its highly-valued range of Maxilact lactase enzymes now includes the new Maxilact Next, a lactase that produces lactose-free milk even faster, allowing its customers to achieve an additional 25% reduction in hydrolysis time.
The global leader in nutrition, health and beauty, today says Maxilact Next is the fastest pure lactase now available on the market which empowers lactose-free milk producers to optimise production, increase capacity and use raw materials more efficiently – all without affecting the taste of lactose-free milk products. It joins the existing Maxilact range, an extensive portfolio based on the company’s more than 50 years’ experience leading lactose-free dairy production.
The introduction is designed to unlock the potential in the lactose-free dairy market with 70% of consumers worldwide unable to properly digest lactose. Lactose-free products are vital for ensuring everyone can fully enjoy nutritious dairy products.
Forecasts predict that lactose-free dairy will achieve a CAGR more than double that of regular dairy between 2022 and 2026, eventually exceeding a value of €10.6 billion. This creates fresh opportunities for dairy producers while also emphasising the need for a swifter and more efficient production process. Manufacturers require first-class lactase solutions to optimise their raw material usage, increase yield and productivity and maintain the highest quality standards.
“We’re proud to introduce Maxilact Next to the market – the fastest, purest, most efficient lactase enzyme solution in our portfolio yet,” comments Rodolfo Garza, global business development manager milk & plant-based alternatives at dsm-firmenich. “In the current market context, efficiency is crucial to keep up with demand and stay cost effective. Our Maxilact range delivers optimised capacity without significant capex investment while maintaining the high quality that consumers expect. Maxilact Next is a great example of a game-changing lactase solution which truly addresses a market pain point.”
